| Dolutegravir or darunavir in combination with zidovudine or tenofovir to treat HIV NI Paton, J Musaazi, C Kityo, S Walimbwa, A Hoppe, A Balyegisawa, ... New England Journal of Medicine 385 (4), 330-341, 2021 | 127 | 2021 |
| Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2 … V Avataneo, A de Nicolo, J Cusato, M Antonucci, A Manca, A Palermiti, ... Journal of Antimicrobial Chemotherapy 75 (7), 1772-1777, 2020 | 92 | 2020 |
| Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 … NI Paton, J Musaazi, C Kityo, S Walimbwa, A Hoppe, A Balyegisawa, ... The Lancet HIV 9 (6), e381-e393, 2022 | 91 | 2022 |
| Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: a randomised trial (DolPHIN-1 study) C Waitt, C Orrell, S Walimbwa, Y Singh, K Kintu, B Simmons, ... PLoS medicine 16 (9), e1002895, 2019 | 87 | 2019 |
| Possible misdiagnosis of HIV associated lymphoma as tuberculosis among patients attending Uganda Cancer Institute P Buyego, L Nakiyingi, H Ddungu, S Walimbwa, D Nalwanga, ... AIDS research and therapy 14, 1-6, 2017 | 36 | 2017 |
| Drug interactions between dolutegravir and artemether-lumefantrine or artesunate-amodiaquine SI Walimbwa, M Lamorde, C Waitt, J Kaboggoza, L Else, ... Antimicrobial agents and chemotherapy 63 (2), 10.1128/aac. 01310-18, 2019 | 23 | 2019 |
| An individual participant data population pharmacokinetic meta-analysis of drug-drug interactions between lumefantrine and commonly used antiretroviral treatment J Francis, KI Barnes, L Workman, T Kredo, LS Vestergaard, RM Hoglund, ... Antimicrobial agents and chemotherapy 64 (5), 10.1128/aac. 02394-19, 2020 | 19 | 2020 |
| Infant exposure to dolutegravir through placental and breast milk transfer: a population pharmacokinetic analysis of DolPHIN-1 L Dickinson, S Walimbwa, Y Singh, J Kaboggoza, K Kintu, M Sihlangu, ... Clinical Infectious Diseases 73 (5), e1200-e1207, 2021 | 18 | 2021 |
| Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults M Lamorde, S Walimbwa, P Byakika-Kibwika, M Katwere, L Mukisa, ... Journal of Antimicrobial Chemotherapy 70 (5), 1482-1486, 2015 | 18 | 2015 |
| Dolutegravir pharmacokinetics during co-administration with either artemether/lumefantrine or artesunate/amodiaquine AN Kawuma, SI Walimbwa, G Pillai, S Khoo, M Lamorde, RE Wasmann, ... Journal of Antimicrobial Chemotherapy 76 (5), 1269-1272, 2021 | 5 | 2021 |
| DolPHIN-1: dolutegravir versus efavirenz when initiating treatment in late pregnancy C Waitt, S Walimbwa, C Orrell, M Lamorde, C Heiberg, U Mehta Conference on Retroviruses and Opportunistic Infections (CROI). Boston …, 2018 | 5 | 2018 |
| Pharmacokinetics of levonorgestrel and etonogestrel contraceptive implants over 48 weeks with rilpivirine-or darunavir-based antiretroviral therapy S Nakalema, CA Chappell, M Pham, P Byakika-Kibwika, J Kaboggoza, ... Journal of Antimicrobial Chemotherapy 77 (11), 3144-3152, 2022 | 4 | 2022 |
| “You would not be in a hurry to go back home”: patients’ willingness to participate in HIV/AIDS clinical trials at a clinical and research facility in Kampala, Uganda DE Sebatta, G Siu, HW Nabeta, G Anguzu, S Walimbwa, M Lamorde, ... BMC Medical Ethics 21, 1-14, 2020 | 4 | 2020 |
| An open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the … SI Walimbwa, JP Kaboggoza, C Waitt, P Byakika-Kibwika, A D’Avolio, ... Trials 22, 1-13, 2021 | 3 | 2021 |
| DolPHIN-1: Randomised controlled trial of dolutegravir (DTG)-versus efavirenz (EFV)-based therapy in mothers initiating antiretroviral treatment in late pregnancy C Orrell, K Kintu, JA Coombs, A Amara, L Myer, J Kaboggoza, B Simmons, ... 22nd International AIDS Conference, 2018 | 3 | 2018 |
| Beyond glycan barriers: non-cognate ligands and protein mimicry approaches to elicit broadly neutralizing antibodies for HIV-1 SI Walimbwa, P Maly, LR Kafkova, M Raska Journal of Biomedical Science 31 (1), 83, 2024 | | 2024 |
| Genetic factors associated with tuberculosis-related clinical outcomes in HIV-infected Black African patients: a systematic review and meta-analysis IG Asiimwe, D Kiiza, S Walimbwa, CW Sekaggya Pharmacogenomics 22 (15), 997-1017, 2021 | | 2021 |
| COVID-19 and infectious diseases. S Okware, SI Walimbwa | | 2020 |
| Drug-drug Interactions between Lumefantrine and Commonly-used Antiretroviral Treatment: An Individual Participant Data Population Pharmacokinetic Meta-Analysis. J Francis, KI Barnes, L Workman, T Kredo, LS Vestergaard, RM Hoglund, ... Antimicrobial Agents and Chemotherapy, 2020 | | 2020 |
| HEALTH WORKFORCE DEVELOPMENT IN EMERGENCY PREPAREDNESS FOR VIRAL HAEMORRHAGIC FEVERS S Okware, B Okware, S Walimbwa, W Omuut, J Nanyondo, I Nabukenya, ... TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE 113, S5-S6, 2019 | | 2019 |
